List of Excipients in Branded Drug VOLTAREN ARTHRITIS PAIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	VOLTAREN ARTHRITIS PAIN	diclofenac sodium	50090-6202	AMMONIA
A-S Medication Solutions	VOLTAREN ARTHRITIS PAIN	diclofenac sodium	50090-6202	CARBOMER HOMOPOLYMER TYPE C
A-S Medication Solutions	VOLTAREN ARTHRITIS PAIN	diclofenac sodium	50090-6202	COCO-CAPRYLATE/CAPRATE

VOLTAREN ARTHRITIS PAIN Excipient Strategy and Commercial Opportunities

Last updated: August 31, 2026

Voltaren Arthritis Pain is an over-the-counter diclofenac sodium topical gel containing 1% diclofenac sodium. Its commercial position depends on three factors: efficient skin delivery, acceptable sensory performance, and regulatory substitutability. The formulation uses a conventional aqueous-alcoholic gel system with penetration-supporting excipients, emollients, a polymeric thickener, and a solubilizing surfactant. The strongest opportunities are lower-cost private-label products, differentiated sensorial formulations, high-compliance packaging, and alternative topical diclofenac delivery systems.

What is Voltaren Arthritis Pain?

Voltaren Arthritis Pain is the U.S. OTC brand for diclofenac sodium topical gel, 1%. Haleon markets the product in the United States. The product is indicated for temporary relief of arthritis pain in joints amenable to topical treatment, including the hand, wrist, elbow, foot, ankle, and knee. It is not intended for immediate relief and may require regular application over several days.[1]

Attribute	Voltaren Arthritis Pain
Active ingredient	Diclofenac sodium
Strength	1% w/w
Dosage form	Topical gel
U.S. regulatory status	OTC product approved through an FDA NDA pathway
Marketed by	Haleon
Therapeutic category	Topical nonsteroidal anti-inflammatory drug
Primary use	Temporary relief of arthritis pain
Typical dosing	2 g for upper-extremity joints; 4 g for lower-extremity joints, applied four times daily
Maximum daily amount	32 g per day across all affected joints
Key commercial competitors	Generic diclofenac sodium topical gel, prescription Voltaren Gel legacy products, topical analgesic alternatives

The product is a small-molecule topical drug, not a biologic. Biosimilar risk therefore does not apply. Competitive risk comes from generic diclofenac gels, branded topical NSAIDs, counterirritant products, patches, creams, sprays, and oral analgesics.

What excipients are used in Voltaren Arthritis Pain?

The FDA label identifies the following inactive ingredients: carbomer homopolymer type C, cocoyl caprylocaprate, isopropyl alcohol, mineral oil, polyoxyl 20 cetostearyl ether, propylene glycol, and purified water.[1]

Excipient	Likely formulation role	Commercial relevance
Carbomer homopolymer type C	Gel-forming polymer and viscosity modifier	Controls spreadability, residence time, dosing feel, and product stability
Cocoyl caprylocaprate	Emollient and lipid-based skin-conditioning agent	Supports skin feel and may assist drug partitioning into the stratum corneum
Isopropyl alcohol	Solvent, volatile vehicle, and sensory modifier	Improves drying time and may enhance drug permeation
Mineral oil	Emollient and occlusive component	Reduces dryness and modifies the skin-contact profile
Polyoxyl 20 cetostearyl ether	Nonionic surfactant and solubilizer	Helps disperse lipophilic components and maintain formulation uniformity
Propylene glycol	Cosolvent, humectant, and potential penetration enhancer	Supports diclofenac solubilization and contributes to skin delivery
Purified water	Primary vehicle	Provides the continuous aqueous phase

The formulation is designed around a balance that is difficult to optimize through a single excipient change. Increasing alcohol or propylene glycol can improve drug solubilization and permeation but may increase irritation or dryness. Increasing carbomer can improve retention but may reduce spreadability and create a tacky or stringy feel. More emollient can improve skin comfort but may slow drying and affect packaging compatibility.

How does the Voltaren Arthritis Pain excipient system work?

Diclofenac sodium is relatively lipophilic despite its salt form. A topical gel must keep the drug sufficiently available in the vehicle while supporting movement across the skin barrier. The Voltaren system addresses this through four formulation functions.

Drug solubilization

Propylene glycol, isopropyl alcohol, water, and polyoxyl 20 cetostearyl ether form a mixed solvent and surfactant environment. This helps maintain diclofenac sodium in a uniform product and reduces the risk of precipitation during storage.

Skin partitioning

Isopropyl alcohol and propylene glycol can influence partitioning between the formulation and the stratum corneum. Cocoyl caprylocaprate and mineral oil alter the lipid environment at the skin surface. The commercial goal is controlled local delivery rather than maximal penetration.

Residence time

Carbomer increases viscosity and holds the gel on the application site. A topical arthritis product must remain on the joint long enough to support dosing without feeling excessively occlusive or difficult to rub in.

Sensory performance

Patients typically judge topical products by drying time, residue, greasiness, odor, tackiness, and ease of application. Isopropyl alcohol supports rapid drying, while mineral oil and the emollient reduce the harsh feel that can accompany an alcohol-rich vehicle.

What formulation opportunities exist around Voltaren Arthritis Pain?

The clearest opportunities involve improving user experience without changing the active ingredient or therapeutic claim.

Low-residue and fast-drying gel

A reformulated gel could reduce tackiness and shorten drying time through changes in solvent ratio, polymer concentration, or volatile co-solvent selection. The main commercial target is adherence to four-times-daily dosing.

The formulation must preserve drug uniformity, viscosity, microbial quality, and skin tolerability. A lower-viscosity product may improve spreadability but can create dosing inconsistency, leakage, or poor control of the applied amount.

Sensitive-skin formulation

A sensitive-skin variant could reduce alcohol, propylene glycol, fragrance, or other irritation-associated components. Voltaren Arthritis Pain's labeled inactive ingredient list does not include fragrance, which already supports a relatively restrained sensory profile.[1]

A lower-irritation formulation could target older patients, patients with fragile skin, and consumers who discontinue treatment because of burning or dryness. Any reformulation would require comparative performance testing because reduced solvent strength can affect drug release and skin permeation.

Enhanced emollient system

A more sophisticated lipid system could improve skin conditioning and reduce dryness. Potential excipient candidates include medium-chain triglycerides, isopropyl myristate, caprylic/capric triglyceride, or other cosmetic-grade emollients. The tradeoff is that heavier emollients can produce an oily residue and slow the product's perceived absorption.

Pump or metered-dose packaging

Packaging is a major commercial opportunity. A metered pump could improve dose reproducibility, reduce contamination, and reduce the need to estimate 2 g or 4 g manually. A pump may also support differentiated claims related to cleanliness and ease of use, subject to FDA substantiation and labeling requirements.

The main development issues are pump calibration, viscosity tolerance, priming, residual product, compatibility with alcohol-containing gels, and accurate delivery across the product's shelf life.

Airless packaging

An airless package could reduce air exposure and improve dispensing from a viscous gel. It may also reduce backflow and contamination. The economics are less favorable than a conventional tube, so the format is more suitable for premium positioning or a clinically differentiated line.

Roll-on, spray, or foam formats

Alternative delivery systems could target consumers who do not want to rub gel into painful joints. A roll-on may improve portability and reduce hand contact. A spray could offer touch-free application, but it creates challenges involving dose measurement, inhalation exposure, overspray, and application to the correct joint.

Foam systems are technically more complex. They require control of propellant, drug distribution, collapse behavior, and dose delivery. The highest commercial probability remains with tube and pump formats because of their lower development risk.

What patents protect Voltaren Arthritis Pain?

The active ingredient, diclofenac, is long off patent. The current commercial opportunity is therefore unlikely to depend on a basic composition-of-matter patent. Potential protection may instead involve formulation claims, topical delivery systems, manufacturing processes, packaging, or brand-related rights.

The FDA label identifies the marketed composition and approved use but does not establish the complete patent position. Orange Book records should be reviewed for listed patents associated with the relevant NDA, while USPTO records should be reviewed for expired, abandoned, pending, or continuation applications involving diclofenac topical formulations.[2][3]

Are the excipients themselves protected?

Most listed excipients are commodity materials with extensive prior art. Carbomer, propylene glycol, mineral oil, purified water, isopropyl alcohol, and common nonionic surfactants generally do not create a strong standalone exclusivity position.

Patent strength would more likely arise from:

• Specific concentration ranges
• Defined solvent-to-emollient ratios
• Drug release or skin-flux profiles
• Reduced irritation or improved tolerability
• Low-residue sensory properties
• Stable diclofenac suspensions or solutions
• Metered-dose delivery systems
• Packaging and container-closure combinations
• Manufacturing processes that prevent precipitation or viscosity drift

An excipient substitution can avoid literal infringement of a narrow composition claim, but it may introduce regulatory comparability and performance risk. A formulation that is materially different from the reference product may require more extensive drug-release, irritation, permeation, stability, and clinical support.

What is the FDA regulatory status of Voltaren Arthritis Pain?

Voltaren Arthritis Pain is an OTC diclofenac sodium topical product approved by FDA. The OTC switch expanded access from the historical prescription market to consumer self-care. The product retains NSAID class warnings, including warnings regarding cardiovascular and gastrointestinal risks associated with NSAIDs.[1][4]

The FDA pathway matters commercially because diclofenac sodium topical gel is not simply a cosmetic topical product. A competing manufacturer must address active-ingredient identity, strength, dosage form, route of administration, labeling, manufacturing controls, and bioequivalence or other applicable regulatory requirements.

Is diclofenac topical gel covered by an OTC monograph?

Voltaren Arthritis Pain was approved through an NDA-based OTC switch rather than relying solely on a general topical analgesic monograph. A competitor seeking a directly substitutable product must evaluate the applicable ANDA or NDA pathway and the reference product's regulatory status. FDA's Orange Book identifies approved drug products and relevant patent or exclusivity information.[2]

When does Voltaren Arthritis Pain lose exclusivity?

The product's principal commercial barriers are unlikely to be active-ingredient exclusivity. Diclofenac has been marketed for decades, and generic topical diclofenac products already compete in the U.S. market.

The relevant exclusivity analysis is product-specific:

Exclusivity category	Relevance to Voltaren Arthritis Pain
New chemical entity exclusivity	Not relevant to long-marketed diclofenac
Orphan-drug exclusivity	Not relevant
Biologic exclusivity	Not relevant
Pediatric exclusivity	Must be checked against current FDA records
Formulation patent term	Depends on listed patents and applicable term adjustments
Method-of-use patents	Must be evaluated against approved labeling and Orange Book listings
Trademark protection	Applies to the Voltaren and Voltaren Arthritis Pain brands, not the active ingredient
Trade dress	May protect packaging presentation but does not block generic formulation entry

There is no biosimilar pathway for this product. Generic entry risk is therefore materially higher than for a biologic topical product and depends primarily on formulation similarity, regulatory approval, manufacturing scale, and retail access.

Which companies are challenging Voltaren Arthritis Pain?

The competitive challenge comes primarily from generic manufacturers rather than from biosimilar developers. U.S. generic diclofenac sodium topical gel suppliers can compete on price, retailer contracts, pharmacy substitution, and private-label distribution.

Relevant competitor groups include:

• Large generic drug manufacturers with topical manufacturing capacity
• Contract manufacturers supplying retailer store brands
• Branded topical analgesic companies
• Digital and specialty pharmacies offering lower-cost generic alternatives
• International suppliers adapting diclofenac gels to regional markets

The strongest commercial threat is a low-cost product with equivalent 1% strength, acceptable application characteristics, and broad pharmacy or mass-retail distribution. A generic does not need to reproduce every excipient if it can satisfy applicable FDA requirements and demonstrate acceptable equivalence.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can capture value in four areas.

Functional excipient systems

A prequalified solvent, emollient, surfactant, and polymer package could shorten formulation development. Suppliers can offer performance data on viscosity, drug release, skin tolerability, and stability rather than selling individual ingredients alone.

Specialty carbomer grades

Polymer suppliers can differentiate grades by lower tack, faster hydration, improved electrolyte tolerance, or better dispensing through pumps. A carbomer designed for topical NSAID gels could support licensing or formulation partnerships.

Skin-compatible penetration systems

A proprietary combination of solvents and emollients may offer a stronger commercial position than a single excipient. The value depends on demonstrated improvement in diclofenac release or skin delivery without increased irritation.

Sustainable and supply-secure excipients

Manufacturers may seek alternatives to petrochemical-derived mineral oil or improve sourcing resilience for surfactants and emollients. Sustainability claims must not compromise regulatory quality, impurity control, or performance.

How strong is the commercial patent estate for an improved diclofenac gel?

A new diclofenac gel can have a commercially useful patent position if it claims a specific and measurable technical advantage. Stronger claim categories include:

1. A defined composition with narrow excipient ranges.
2. A reproducible drug-release or skin-flux profile.
3. Reduced skin irritation demonstrated in controlled testing.
4. A novel metered-dose package.
5. A stable formulation with improved shelf life.
6. A manufacturing process that produces a nonprecipitating, uniform gel.

Weak claims include broad use of common excipients without a demonstrated unexpected result. A formulation based only on replacing one conventional solvent with another is vulnerable to obviousness and design-around arguments.

What generic launch scenarios exist?

Three launch models are commercially plausible.

Low-cost generic tube

This model prioritizes FDA approval, low manufacturing cost, standard packaging, and pharmacy substitution. It presents the greatest price pressure against Voltaren Arthritis Pain.

Retailer private label

A retailer or pharmacy chain can pair a generic diclofenac gel with high-volume distribution and lower marketing expense. Private-label products are particularly competitive in mass retail and online channels.

Premium differentiated topical

A manufacturer can use a pump, sensitive-skin positioning, improved sensory properties, or a more convenient application system. This model supports higher gross margins but requires consumer education and evidence supporting the differentiation.

What manufacturing and IP barriers affect entry?

Manufacturing barriers are moderate. The formulation does not depend on a biologic process or complex sterile delivery system. The main technical risks are:

• Maintaining uniform diclofenac distribution
• Preventing precipitation during storage
• Controlling carbomer hydration and viscosity
• Managing alcohol evaporation
• Ensuring tube or pump compatibility
• Demonstrating preservative and microbial control
• Reproducing application and drug-release performance
• Scaling mixing without introducing air or batch variation

The most defensible IP is likely to sit at the intersection of formulation performance and packaging. Commodity excipients alone provide limited protection.

Key Takeaways

• Voltaren Arthritis Pain is a 1% diclofenac sodium topical gel marketed by Haleon.
• Its excipient system combines carbomer, solvents, emollients, a surfactant, and water.
• The principal formulation challenge is balancing skin delivery, drying time, spreadability, residue, and tolerability.
• Diclofenac's composition-of-matter exclusivity is not the main barrier to competition.
• Generic and private-label entry risk is substantial because the product is a small-molecule topical drug.
• The most credible innovation opportunities are sensitive-skin gels, lower-residue systems, metered pumps, airless packaging, and specialized excipient platforms.
• Strong new patent claims would need to cover a defined composition, measurable delivery advantage, packaging system, or manufacturing benefit.
• Biosimilar competition is irrelevant; generic substitution is the relevant threat.
• FDA Orange Book and USPTO review is required for a current patent and exclusivity determination.

FAQs

Can a company sell a Voltaren-like diclofenac gel without using the same excipients?

Yes. A competing product may use different inactive ingredients if it meets FDA requirements for safety, quality, labeling, dosage form, and equivalence. The alternative formulation must still provide acceptable product performance.

Does using a different carbomer avoid all Voltaren formulation patents?

No. A different carbomer may avoid a narrow composition claim, but infringement depends on the language of each issued patent. A patent may cover excipient ranges, performance characteristics, manufacturing steps, or packaging rather than a single polymer grade.

Is a diclofenac gel eligible for an abbreviated new drug application?

Potentially. The appropriate pathway depends on the reference listed drug, dosage form, strength, labeling, formulation differences, and FDA requirements in effect at filing. A sponsor must evaluate the current Orange Book and FDA product-specific guidance.

Can a pump package create new patent protection for diclofenac gel?

Yes, if the pump and formulation combination has patentable structure or function. Examples include calibrated dosing, viscosity-compatible dispensing, reduced contamination, or a package that preserves formulation stability.

What is the highest-value excipient opportunity in a generic Voltaren product?

A performance-based excipient system that improves drying, spreadability, skin tolerability, and dose consistency has greater value than a simple substitution of one commodity solvent for another. The system would need supporting stability, release, permeation, and tolerability data.

References

1. U.S. Food and Drug Administration. (2023). Voltaren Arthritis Pain: Diclofenac sodium topical gel, 1% prescribing information and Drug Facts labeling. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. United States Patent and Trademark Office. (n.d.). Patent Public Search. https://ppubs.uspto.gov/pubwebapp/

4. U.S. Food and Drug Administration. (2020). FDA approves first over-the-counter topical diclofenac gel for arthritis pain. https://www.fda.gov/ ---